Newsroom

Press Release

NeoGenomics Schedules its Q1 2014 Earnings Release for April 23, 2014

NeoGenomics Announces Next Generation Sequencing Tests for Solid Tumor Cancers and Myelodysplastic Syndrome

NeoGenomics Reports Record Revenue of $18.3 Million, Adjusted EBITDA of $2.7 Million and Net Income of $0.02 per Share for the Fourth Quarter 2013

NeoGenomics Launches 22 New Cancer Genomic Tests Designed for Actionable Profiling of Various Hematologic and Solid Cancers

NeoGenomics Schedules its Q4 2013 and Full Year 2013 Earnings Release for February 19, 2014

NeoGenomics is the First Laboratory to Offer Calreticulin (CALR) Mutation Testing for the Diagnosis and Classification of Myeloproliferative Neoplasms

NeoGenomics Reports Record Revenue of $16.9 Million, Adjusted EBITDA of $2.2 Million and Net Income of $900K for the Third Quarter 2013

NeoGenomics Schedules its Q3 2013 Earnings Release for October 23, 2013

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients